Gilead Sciences Stock Slips on Possible HIV Funding Cut

Core Viewpoint - Gilead Sciences Inc (NASDAQ:GILD) has experienced a significant decline in stock price due to potential funding cuts for domestic HIV prevention programs by the Trump administration, impacting the company's core business in HIV and AIDS treatments [1][2]. Group 1: Stock Performance - GILD's stock is down 2.6% to $107.34, marking its lowest level since mid-February [1]. - The stock has pulled back from a nine-year high of$119.96 reached on March 10, now facing its seventh loss in eight sessions [2]. - Despite the recent decline, GILD remains up 46.2% year-over-year and 16.3% year-to-date [2]. Group 2: Options Activity - There has been a notable increase in put options activity, with 3,000 puts exchanged today, double the typical volume [2]. - The March 103 put option is the most popular, indicating bearish sentiment as new positions are being opened [2]. - GILD's 10-day put/call volume ratio of 0.95 ranks higher than 99% of readings from the past year, suggesting heightened bearish activity [3].